Taiko Pharmaceutical Co.,Ltd.
JPX: 4574.T0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Tokyo Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Takashi Shibata
- Employees
- 214
- Headquarters
- Osaka, Japan
- IPO year
- 2009
- Market cap
- ¥14.7B
- Website
- https://www.seirogan.co.jp
Loading 4574…
Loading profile data…Frequently asked questions about 4574
What does Taiko Pharmaceutical Co.,Ltd. (4574.T) do?
Taiko Pharmaceutical Co.,Ltd. engages in pharmaceuticals, infection control, and other businesses. The company manufactures and sells non-prescription drugs under the Seirogan and Seirogan Toi-A brands for the treatment of loose stools, diarrhea, food and water poisoning, vomiting, and related conditions; tablets for diarrhea; and quasi-drugs, s...
Where does 4574.T trade?
Taiko Pharmaceutical Co.,Ltd. (4574.T) trades on the Tokyo Stock Exchange.
What sector is 4574.T in?
Taiko Pharmaceutical Co.,Ltd. (4574.T) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Taiko Pharmaceutical Co.,Ltd.?
Takashi Shibata is the chief executive officer of Taiko Pharmaceutical Co.,Ltd. (4574.T).
Where is Taiko Pharmaceutical Co.,Ltd. headquartered?
Taiko Pharmaceutical Co.,Ltd. is headquartered in Japan.
Does 4574.T pay a dividend?
Yes — Taiko Pharmaceutical Co.,Ltd. (4574.T) paid a trailing twelve-month dividend of JPY 3.30 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 4574.T go public?
Taiko Pharmaceutical Co.,Ltd. (4574.T) completed its initial public offering in 2009.